Greystone Research Associates
Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and reach their financial targets.
Our reports are carefully researched and written to provide timely and insightful analysis of key factors and developments shaping the commercial marketplace. The focused nature of our publications is designed to allow readers to identify emerging demand and growth opportunities in selected markets. Numerous charts, tables and graphs complement the text, with evaluations and assessments of current and probable future market developments, technology issues and business factors - information necessary to compete effectively in the global marketplace.
|

|
List of reports from Greystone Research Associates
Prefilled Syringes to 2018
3/1/2013 | published by: Greystone Research Associates
... powerful therapeutic drugs and healthcare administration initiatives. Population demographics and efforts by managed care providers to control healthcare costs are driving the growth in drug self-administration, particularly for chronic conditions, introducing a new class of ...
|
read more...
|
$3,850.00
|
Injectable Drug Delivery to 2018
3/1/2013 | published by: Greystone Research Associates
... levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges ...
|
read more...
|
$4,850.00
|
Point-of-Delivery Drug Reconstitution Systems to 2017
1/1/2013 | published by: Greystone Research Associates
... temperatures and to preserve their shelf life must be either stored at low temperature (the so-call 'cold chain') or processed into a form that will preserve their pharmacological efficacy until they reach their therapeutic destination. ...
|
read more...
|
$3,850.00
|
Closed Drug Transfer Systems
1/1/2013 | published by: Greystone Research Associates
... area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that – in spite of promising new drugs based on therapeutic antibodies – continues to rely ...
|
read more...
|
$2,850.00
|
|
|
$4,850.00
|
Integrated Safety Syringes to 2016
5/1/2012 | published by: Greystone Research Associates
... for a sharps disposal step. Safety syringes address caregiver preferences and mitigate the cost premium associated with retractable models. While more than fifty companies compete in the safety syringe sector, only a handful companies manufacture ...
|
read more...
|
$2,850.00
|
Prefilled Syringes to 2016
4/1/2012 | published by: Greystone Research Associates
... commercially. For Fill-and-Finish contractors, market proximity is an important competitive factor, and the past twelve months has seen major prefilled syringe CMOs expanding their operations in regional markets, particularly in North America. This report analyzes ...
|
read more...
|
$3,850.00
|
Needle Array Drug Delivery Systems
2/1/2012 | published by: Greystone Research Associates
... and by the need for safer, more reliable drug products that improve compliance. For drugs designed to be delivered across the skin, needle arrays are viewed as an approach that addresses these key healthcare objectives. ...
|
read more...
|
$2,850.00
|
Dual Chamber Injectors & Syringes
1/1/2012 | published by: Greystone Research Associates
... stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the ‘Cold ...
|
read more...
|
$2,850.00
|
Drug Self-Administration Markets to 2016
1/1/2012 | published by: Greystone Research Associates
... new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery ...
|
read more...
|
$4,850.00
|
Drug Reconstitution at the Point-of-Care
1/1/2012 | published by: Greystone Research Associates
... behind the innovative approaches that address the growing need for packaging and delivering lyophilized drugs for injection. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and ...
|
read more...
|
$3,850.00
|
Active Transdermal Delivery Systems
10/15/2011 | published by: Greystone Research Associates
... and business strategies Charts product sales data, market share, and forecasts to 2015 Profiles active transdermal delivery companies, their product development activities, business strategies, and corporate alliances and affiliations Assesses the importance of pharma-device alliances ...
|
read more...
|
$2,850.00
|
Microneedle Drug Delivery
5/1/2011 | published by: Greystone Research Associates
... well as for integration with other miniaturized biochemical analysis systems. The needles are enabling for the manipulation of micro volumes of samples as well as for parallel distribution of samples or reagents on a close ...
|
read more...
|
$2,850.00
|
Drug Cartridge-based Syringes & Injectors
4/1/2011 | published by: Greystone Research Associates
... and injectors have evolved considerable to address the changing demands of clinicians and their patients. In particular, the appearance and refinement of disposable drug cartridges has created unique opportunities for developers of injectable drugs. Prefilled ...
|
read more...
|
$3,850.00
|
Prefilled Syringes
4/1/2011 | published by: Greystone Research Associates
... commercially. For Fill-and-Finish contractors, market proximity is an important competitive factor, and the past twelve months has seen major prefilled syringe CMOs expanding their operations in regional markets, particularly in North America. This report analyzes ...
|
read more...
|
$3,850.00
|
Dry Powder Inhalation
2/1/2011 | published by: Greystone Research Associates
... therapies is focused on chronic diseases and refractory conditions - aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to, and systematically via, the lungs ...
|
read more...
|
$3,850.00
|
Drug Solubility Technology and Platforms
1/1/2011 | published by: Greystone Research Associates
... drug development. This impact extends beyond potential future drug therapeutics, affecting current reformulation strategies as well. As large-molecule therapeutics increase in number and as a percentage of all drug discoveries, the economic scales will tip ...
|
read more...
|
$3,850.00
|
Point-of-Delivery Drug Reconstitution Systems
1/1/2011 | published by: Greystone Research Associates
... the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed - a distribution strategy referred to as the ‘Cold Chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins ...
|
read more...
|
$3,850.00
|
Autoinjectors
1/1/2011 | published by: Greystone Research Associates
... recently, autoinjectors were designed to be reused. The reason was that the injectors were too expensive to be successfully marketed as a throw-away device. Recent improvements in materials technology and device design have led to ...
|
read more...
|
$2,850.00
|
Delivering Drugs by Inhalation
12/1/2010 | published by: Greystone Research Associates
... have each found a niche in the quest for optimal treatment and convenient use. While nebulizers have evolved relatively independently of the drug formulations they deliver, the current generation of MDIs and DPIs have been ...
|
read more...
|
$3,850.00
|
|
|
$3,850.00
|
Therapeutic Proteins to 2014
11/15/2010 | published by: Greystone Research Associates
... becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively ...
|
read more...
|
$4,850.00
|
Pen Injectors
11/15/2010 | published by: Greystone Research Associates
... syringes. Advances in synthetic materials and concurrent development partnerships between pen designers and drug developers are important factors in the growth of this segment. With detailed product summariess, industry data and forecasts, pen injector company ...
|
read more...
|
$3,850.00
|
Injectable Drug Delivery
11/1/2010 | published by: Greystone Research Associates
... levels of the healthcare sector. The injectable drug segment has seen a marked increase in the level of drug/device integration, as prefilled syringes and specialized injection devices proliferate in response to safety and economic challenges ...
|
read more...
|
$3,850.00
|
Drug Self-Administration Markets to 2014
11/1/2010 | published by: Greystone Research Associates
... new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery technologies. Now a number of factors are converging to create both risk and opportunity for drug makers and their delivery ...
|
read more...
|
$4,850.00
|
|
Join Alert Me now! Receive bi-weekly email alerts on new market research Sign up today!
|